Amgen Announces FDA Advisory Committee Meeting To Review Potential New Use Of BLINCYTO ® (blinatumomab)

First-Ever Application to be Submitted for an MRD Positive Indication THOUSAND OAKS, Calif., Feb. 14, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) will review data supporting the BLINCYTO® (blinatumomab) supplemental Biologics License Application (sBLA) for the treatment of patients with minimal residual disease (MRD)-positive B-cell precursor acute lymphoblastic leukemia (ALL) at a meeting on March 7, 2018. MRD refers to the presence of a small amount of detectible cancer cells that remain in the patient after treatment. "After achieving remission, the presence of MRD is the st...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news